These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 11904783)

  • 21. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.
    Kuderer NM; Dale DC; Crawford J; Cosler LE; Lyman GH
    Cancer; 2006 May; 106(10):2258-66. PubMed ID: 16575919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of febrile neutropenia in pediatric oncology patients: a Canadian survey.
    Boragina M; Patel H; Reiter S; Dougherty G
    Pediatr Blood Cancer; 2007 May; 48(5):521-6. PubMed ID: 16724314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.
    Lyman GH; Kuderer NM
    Crit Rev Oncol Hematol; 2004 May; 50(2):129-46. PubMed ID: 15157662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Balancing the benefits and costs of antibiotic drugs: the TREAT model.
    Leibovici L; Paul M; Andreassen S
    Clin Microbiol Infect; 2010 Dec; 16(12):1736-9. PubMed ID: 20673259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Decision analysis in antibiotic therapy].
    Calvo MV; Domínguez-Gil A
    Enferm Infecc Microbiol Clin; 1990 Apr; 8(4):199-207. PubMed ID: 2128607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new ciprofloxacin stepdown program in the treatment of high-risk febrile neutropenia: a clinical and economic analysis.
    Marra CA; Frighetto L; Quaia CB; de Lemos ML; Warkentin DI; Marra F; Jewesson PJ
    Pharmacotherapy; 2000 Aug; 20(8):931-40. PubMed ID: 10939554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost effective approaches to antimicrobial use in oncology patients.
    Goff DA
    Curr Opin Infect Dis; 2002 Dec; 15(6):565-8. PubMed ID: 12821831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of febrile neutropenia is expensive: prevention is the answer.
    Klastersky JA; Paesmans M
    Onkologie; 2011; 34(5):226-8. PubMed ID: 21577026
    [No Abstract]   [Full Text] [Related]  

  • 29. Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer.
    Castagnola E; Paola D; Giacchino R; Rossi R; Viscoli C
    Support Care Cancer; 1998 Nov; 6(6):524-8. PubMed ID: 9833301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current attitudes for therapy of febrile neutropenia with consideration to cost-effectiveness.
    Klastersky J
    Curr Opin Oncol; 1998 Jul; 10(4):284-90. PubMed ID: 9702394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial.
    Hendricks AM; Loggers ET; Talcott JA
    J Clin Oncol; 2011 Oct; 29(30):3984-9. PubMed ID: 21931037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The costs of treating febrile neutropenia in patients with malignant blood disorders.
    Leese B; Collin R; Clark DJ
    Pharmacoeconomics; 1994 Sep; 6(3):233-9. PubMed ID: 10155266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No place like home? Outpatient management of patients with febrile neutropenia and low risk.
    Freifeld AG; Sepkowitz KA
    J Clin Oncol; 2011 Oct; 29(30):3952-4. PubMed ID: 21931028
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre.
    Teh BW; Brown C; Joyce T; Worth LJ; Slavin MA; Thursky KA
    Support Care Cancer; 2018 Mar; 26(3):997-1003. PubMed ID: 29018966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cost effective approach to treatment of infection: "switch therapy".
    Burnakis TG
    Hosp Pharm; 1992 Apr; 27(4):353-4, 360. PubMed ID: 10117773
    [No Abstract]   [Full Text] [Related]  

  • 36. Ambulatory management of low-risk febrile neutropenia in adult oncological patients. Systematic review.
    Forcano-Queralt E; Lemes-Quintana C; Orozco-Beltrán D
    Support Care Cancer; 2023 Nov; 31(12):665. PubMed ID: 37921996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A model for cost evaluation of new antibiotics.
    Feldman M; Moura R; Sharon D; Daly J; Lynch M; Worthington M
    Arch Intern Med; 1989 Jul; 149(7):1698. PubMed ID: 2742447
    [No Abstract]   [Full Text] [Related]  

  • 38. Staying plugged in. Where to find aid for utility costs.
    Ludlow J
    Posit Living; 2001 Feb; 10(2):6. PubMed ID: 11548501
    [No Abstract]   [Full Text] [Related]  

  • 39. Morals, science and chance.
    Drew LR
    Drug Alcohol Rev; 1991; 10(3):277-82. PubMed ID: 16840057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adventures in Mailing Science.
    Moulton FR
    Science; 1948 Nov; 108(2813):606-7. PubMed ID: 17752380
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.